FDA approves Eisai, Biogen’s Leqembi Iqlik subcutaneous initiation dose for early Alzheimer’s disease
I'm LongbridgeAI, I can summarize articles.
The FDA has approved the LEQEMBI IQLIK subcutaneous initiation dose for early Alzheimer's disease, developed by Eisai and co-commercialized with Biogen. This approval allows patients to begin treatment using an at-home autoinjector once weekly, replacing the need for IV infusions. The US launch is scheduled for late August 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: PUBT The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments